Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Quince Therapeutics Inc.

    NASDAQ: QNCX · Real-Time Price · USD
    1.42
    0.22 (18.33%)
    At close: Jun 13, 2025, 3:59 PM
    1.30
    -8.13%
    After-hours: Jun 13, 2025, 05:59 PM EDT

    Quince Therapeutics Statistics

    Share Statistics

    Quince Therapeutics has 45.47M shares outstanding. The number of shares has increased by 1.82% in one year.

    Shares Outstanding

    n/a
    		 45.47M

    Shares Change (YoY)

    n/a
    		 1.82%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 35M

    Failed to Deliver (FTD) Shares

    n/a
    		 13,929

    FTD / Avg. Volume

    n/a
    		 4.86%

    Short Selling Information

    The latest short interest is 506.94K, so 1.11% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 506.94K

    Short % of Shares Out

    n/a
    		 1.11%

    Short % of Float

    n/a
    		 1.28%

    Short Ratio (days to cover)

    n/a
    		 2.57

    Valuation Ratios

    The PE ratio is -1.42 and the forward PE ratio is -1.74. Quince Therapeutics's PEG ratio is -0.03.

    PE Ratio

    n/a
    		 -1.42

    Forward PE

    n/a
    		 -1.74

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.3

    PB Ratio

    n/a
    		 2.68

    P/FCF Ratio

    n/a
    		 -2.52

    PEG Ratio

    n/a
    		 -0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Quince Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.05, with a Debt / Equity ratio of 0.49.

    Current Ratio

    n/a
    		 6.05

    Quick Ratio

    n/a
    		 6.05

    Debt / Equity

    n/a
    		 0.49

    Debt / EBITDA

    n/a
    		 -0.26

    Debt / FCF

    n/a
    		 -0.46

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,578,555.56

    Employee Count

    n/a
    		 36

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 87K

    Effective Tax Rate

    n/a
    		 -0.15%

    Stock Price Statistics

    The stock price has increased by 100% in the last 52 weeks. The beta is 0.8, so Quince Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.8

    52-Week Price Change

    n/a
    		 100%

    50-Day Moving Average

    n/a
    		 1.08

    200-Day Moving Average

    n/a
    		 1.31

    Relative Strength Index (RSI)

    n/a
    		 72.82

    Average Volume (20 Days)

    n/a
    		 286,893

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -57.28M

    Net Income

    n/a
    		 -56.83M

    EBITDA

    n/a
    		 -56.55M

    EBIT

    n/a
    		 -56.74M

    Earnings Per Share (EPS)

    n/a
    		 -1.31
    Full Income Statement

    Balance Sheet

    The company has 6.21M in cash and 14.81M in debt, giving a net cash position of -8.6M.

    Cash & Cash Equivalents

    n/a
    		 6.21M

    Total Debt

    n/a
    		 14.81M

    Net Cash

    n/a
    		 -8.6M

    Retained Earnings

    n/a
    		 -376.47M

    Total Assets

    n/a
    		 107.09M

    Working Capital

    n/a
    		 25.47M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -31.9M and capital expenditures -257K, giving a free cash flow of -32.16M.

    Operating Cash Flow

    n/a
    		 -31.9M

    Capital Expenditures

    n/a
    		 -257K

    Free Cash Flow

    n/a
    		 -32.16M

    FCF Per Share

    n/a
    		 -0.74
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    QNCX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for QNCX is $9.5, which is 569% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $9.5

    Price Target Difference

    n/a
    		 569%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -5.82

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist